Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951474 | 1.00 | TAAR1 (0.50) | TAAR1IDO1AGXTMIFALDH1A1 | |
| SCHEMBL407367 | 0.84 | DHFR (0.39) | TAAR1ALDH1A1SLC6A3MAOBMEN1 | |
| SCHEMBL29950911 | 0.79 | TAAR1 (0.57) | TAAR1IDO1AGXTMIFALDH1A1 | |
| SCHEMBL29957293 | 0.77 | IDO1 (0.41) | IDO1 | |
| SCHEMBL168131 | 0.76 | — | — | |
| SCHEMBL29953051 | 0.74 | PNMT (0.54) | TAAR1IDO1AGXT | |
| SCHEMBL1550703 | 0.74 | TAAR1 (0.50) | TAAR1IDO1AGXTSMN1; SMN2MAOB | |
| SCHEMBL2992299 | 0.74 | PNMT (0.54) | TAAR1IDO1AGXT | |
| SCHEMBL29951478 | 0.74 | TAAR1 (0.50) | TAAR1IDO1AGXTSMN1; SMN2MAOB | |
| SCHEMBL29956498 | 0.74 | TAAR1 (0.50) | TAAR1IDO1ALDH1A1MAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334315-B2 | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110003795-A1 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| EP-0195939-B1 | IMIDAZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-12 | — | — | EP | disclosed |
| US-4616010-A | ANXIOLYTIC, ANTICONJULSANT, MUSCLE RELAXANT, AND SEDATIVE | HOFFMANN-LA ROCHE INC. (US) | 1986-10-07 | — | — | US | disclosed |
| EP-0195939-A2 | Imidazodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003795-A1 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands | TRPV1, UTS2R, CNR2 | TAAR1 194/4885IDO1 2476/4885AGXT 3321/4885 |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | TAAR1 199/4885IDO1 3073/4885AGXT 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.